Healthcare Resource Utilization and Costs of Rivaroxaban Versus Warfarin Among Non-valvular Atrial Fibrillation (NVAF) Patients with Diabetes in a US Population

INTRODUCTION: The healthcare resource utilization (HRU) and costs of oral anticoagulant-naïve patients with non-valvular atrial fibrillation (NVAF) and diabetes initiated on rivaroxaban or warfarin in the United States (US) has not been previously evaluated. METHODS: This retrospective study used da...

Descripción completa

Detalles Bibliográficos
Autores principales: Berger, Jeffrey S., Ashton, Veronica, Laliberté, François, Germain, Guillaume, Bookhart, Brahim, Lejeune, Dominique, Boudreau, Julien, Lefebvre, Patrick, Weir, Matthew R.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2023
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9988717/
https://www.ncbi.nlm.nih.gov/pubmed/36658454
http://dx.doi.org/10.1007/s12325-022-02422-9

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9988717/
https://www.ncbi.nlm.nih.gov/pubmed/36658454
http://dx.doi.org/10.1007/s12325-022-02422-9

Ejemplares similares